Editorially Independent content supported with advertising by Novartis and Alcon.
Reducing Treatment Intervals in Wet AMD
A Breakthrough After Monthly Wet AMD Therapy
Navigating Treatment Burden in Wet AMD
Outside-the-Box Therapy for Wet AMD
Reducing Treatment Intervals in Wet AMD |
A Breakthrough After Monthly Wet AMD Therapy |
Navigating Treatment Burden in Wet AMD |
Outside-the-Box Therapy for Wet AMD |
Arshad M. Khanani, MD, outlines the case of a patient whose wet AMD requires treatment every 4 to 6 weeks. The patient was diagnosed in 2010 and has been administered more than 60 doses of various anti-VEGF agents. The patient underwent therapy with brolucizumab (Beovu, Novartis), and began to experience improved vision and extended duration intervals. Hear a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.